Table 4.
Clinical features of essential thrombocythemia patients according to abdominal aortic calcification.
| Without AAC (N=35) | With AAC (N=59) | P | |
|---|---|---|---|
| Age, yr | 49.4±12.3 | 68.1±10.5 | <0.001 |
| Male | 12 (37.1) | 32 (54.2) | 0.109 |
| Volumetric splenomegaly | 18 (51.4) | 29 (49.2) | 0.831 |
| Laboratory findings | |||
| WBC, ×109/L | 9.7±2.9 | 11.8±4.7 | 0.017 |
| Neutrophil/lymphocyte | 3.2±1.5 | 4.3±2.7 | 0.039 |
| Monocyte, ×109/L | 0.5±0.2 | 0.7±0.5 | 0.003 |
| Hemoglobin, g/dL | 14.0±1.6 | 13.2±2.5 | 0.111 |
| Platelet, ×109/L | 881.3±338.2 | 989.3±412.6 | 0.196 |
| LDH, ×ULN | 1.1±0.4 | 1.3±0.4 | 0.043 |
| Driver gene mutation | |||
| JAK2V617F | 20 (58.8) | 44 (81.5) | 0.020 |
| CALR | 5 (14.3) | 4 (6.8) | 0.232 |
| JAK2V617F VAF, % | 21.8±11.0 | 26.1±13.5 | 0.218 |
| IPSET | <0.001 | ||
| Low | 26 (74.3) | 3 (5.1) | |
| Intermediate | 5 (14.3) | 23 (39.0) | |
| High | 4 (11.4) | 33 (55.9) | |
| R-IPSET-T | <0.001 | ||
| Very low | 11 (31.4) | 1 (1.7) | |
| Low | 17 (48.6) | 6 (10.2) | |
| Intermediate | 1 (2.9) | 10 (16.9) | |
| High | 5 (14.3) | 42 (71.2) | |
| Comorbidity | |||
| Hypertension | 5 (14.3) | 27 (45.8) | 0.002 |
| Diabetes mellitus | 2 (5.7) | 11 (18.6) | 0.079 |
| Chronic kidney disease | 1 (2.9) | 10 (16.9) | 0.030 |
| Dyslipidemia | 3 (8.6) | 16 (27.1) | 0.001 |
| Smoking | 6 (17.1) | 15 (25.4) | 0.351 |
| Thrombotic event | |||
| Arterial | 3 (8.6) | 18 (30.5) | 0.014 |
| Overall | 3 (8.6) | 19 (32.2) | 0.009 |
| Hemorrhagic event | 1 (2.9) | 7 (11.9) | 0.130 |
| Follow-up, yr | 6.3±5.8 | 3.2±3.6 | 0.002 |
Data are presented as number (%) or mean±standard deviation.
Abbreviations: AAC, abdominal aortic calcification; CALR, calreticulin; IPSET, International Prognostic Score in Essential Thrombocythemia; LDH, lactate dehydrogenase; R-IPSET-T, revised IPSET-thrombosis; ULN, upper limit of normal; VAF, variant allele frequency.